Coronary Artery Disease Clinical Trial
— MACEOfficial title:
Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)
NCT number | NCT01930214 |
Other study ID # | CLN-0002-P |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 26, 2013 |
Est. completion date | June 1, 2017 |
Verified date | July 2023 |
Source | Abbott Medical Devices |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this study is to assess the current standard of care treatment outcome in none/mild, moderate and severely calcified coronary lesions using: - A composite of MACE at 30-day and one (1) year post procedure, and - Procedural and lesion success
Status | Completed |
Enrollment | 350 |
Est. completion date | June 1, 2017 |
Est. primary completion date | November 7, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subjects must be at least 18 years of age. 2. Subjects must be scheduled for percutaneous coronary revascularization involving stent deployment in de novo coronary lesions. Percutaneous coronary revascularization is defined as treatment with commercially available devices that may include but not limited to balloon angioplasty, cutting balloon, rotablation, etc. followed by the stent placement. 3. Subjects CK-MB must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to procedure. If CK-MB results are not yet available prior to initiating procedure, subjects Troponin I or Troponin T must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to the procedure. 4. The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure. 5. The target vessel must be a native coronary artery with: 1. A stenosis = 70% and < 100%, or 2. A stenosis = 50% < 70% with evidence of clinical ischemia 6. The target vessel reference diameter must be = 2.5mm and = 4.0 mm. 7. The lesion length must not exceed 40 mm. 8. The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow three (3) at baseline. Exclusion Criteria: 1. Inability to understand the study or a history of non-compliance with medical advice. 2. Unwilling or unable to sign the MACE clinical study ICF. 3. History of any cognitive or mental health status that would interfere with study participation. 4. Currently enrolled in any other pre-approval investigational study. This does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.). 5. Female subjects who are pregnant or planning to become pregnant within the study period. 6. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications. 7. Known sensitivity to contrast media, which cannot be adequately pre-medicated. 8. Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level >2.5 mg/dl. 9. History of major cardiac intervention within 30-day, not including a PCI procedure for a staging purpose. 10. Evidence of heart failure by one of the following: i. Left Ventricular Ejection Fraction (LVEF) = 25% ii. New York Heart Association (NYHA) class III or IV iii. Clinical symptoms 11. History of a stroke or transient ischemic attack (TIA) within six (6) months 12. Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months. 13. History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary. 14. Concurrent medical condition with a life expectancy of < 36 months. 15. History of immune deficiency. 16. Uncontrolled insulin dependent diabetes. 17. Evidence of active infections on the day of the index procedure. 18. Subject has planned cardiovascular intervention within 60 days post index procedure. 19. Subject with angiographically confirmed evidence of more than two (2) lesions within one (1) vessel or more than one (1) vessel requiring intervention, unless the treatment is staged. See Section 10.1 for more details. 20. Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or Left Internal Mammary Artery/ Right Internal Mammary Artery (LIMA/RIMA) bypass. 21. Target vessel has angiographically visible or suspected thrombus. 22. Target vessel appears to be/is excessively tortuous at baseline. 23. Target lesion is an ostial location (within 5mm of ostium) or an unprotected left main lesion. 24. Target lesion is a bifurcation (side branch = 1.5mm). 25. Treatment of the target lesion with the CSI coronary Diamondback Orbital Atherectomy System (OAS). |
Country | Name | City | State |
---|---|---|---|
United States | Georgia Regents Research Institute | Augusta | Georgia |
United States | John Hopkins | Baltimore | Maryland |
United States | McLaren Bay Regional | Bay City | Michigan |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | Clearwater Cardiovascular & Interventional Consultants | Clearwater | Florida |
United States | Boone Hospital | Columbia | Missouri |
United States | OhioHealth Research Institute | Columbus | Ohio |
United States | Duke University Medical Center | Durham | North Carolina |
United States | University Pittsburg MC - Hamot | Erie | Pennsylvania |
United States | Glendale Adventist Medical Center | Glendale | California |
United States | East Carolina University | Greenville | North Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Hartford Hospital | Hartford | Connecticut |
United States | Houston Methodist Research Institute | Houston | Texas |
United States | Indiana University | Indianapolis | Indiana |
United States | Saint Luke's | Kansas City | Missouri |
United States | Arkansas Heart Hospital | Little Rock | Arkansas |
United States | University of Tennessee | Memphis | Tennessee |
United States | Mount Sinai Medical Center Heart Institute | Miami Beach | Florida |
United States | Jersey Shore Medical Center | Neptune | New Jersey |
United States | Mission Research Institute | New Braunfels | Texas |
United States | Mount Sinai New York | New York | New York |
United States | Cardiovascular Institute of NW Florida | Panama City | Florida |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | North Carolina Heart & Vascular Specialists | Raleigh | North Carolina |
United States | Beaumont Hospital | Royal Oak | Michigan |
United States | Barnes Jewish Hospital | Saint Louis | Missouri |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | Prairie Education & Research Cooperative | Springfield | Illinois |
United States | St. John Health System | Tulsa | Oklahoma |
United States | Providence Health Center | Waco | Texas |
United States | MedStar Washington Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
United States,
Sharma SK, Bolduan RW, Patel MR, Martinsen BJ, Azemi T, Giugliano G, Resar JR, Mehran R, Cohen DJ, Popma JJ, Waksman R. Impact of calcification on percutaneous coronary intervention: MACE-Trial 1-year results. Catheter Cardiovasc Interv. 2019 Aug 1;94(2): — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MACE at 30 Days | A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 30 days. 30-day MACE is composed of: Cardiac death Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure |
30 days post procedure | |
Secondary | MACE at One (1) Year | A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 1 year. 1-year MACE is composed of: Cardiac death Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure |
One (1) year post procedure | |
Secondary | Procedural Success | Procedural success is defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE. | Participants were followed from baseline procedure through hospital discharge, an expected average of 24 hours | |
Secondary | Lesion Success | Lesion success is defined as success in facilitating stent delivery with a post-procedural result of <50% residual stenosis for a given lesion treated during the procedure without severe angiographic complications. | During the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions
|
N/A |